A detailed history of Seven Mile Advisory transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Seven Mile Advisory holds 2,668 shares of GILD stock, worth $293,346. This represents 0.16% of its overall portfolio holdings.

Number of Shares
2,668
Holding current value
$293,346
% of portfolio
0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$83.95 - $97.9 $223,978 - $261,197
2,668 New
2,668 $246 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $217,457 - $237,250
2,941 New
2,941 $220 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $138B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Seven Mile Advisory Portfolio

Follow Seven Mile Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Mile Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Seven Mile Advisory with notifications on news.